DECURA PHARMA
ActiveDECURA PHARMA is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €3.83M and a net result of €271k. Equity is growing by ~7.9% per year across the filed fiscal years. Its solvency ranks better than 35% of 5491 sector peers (fiscal year 2025). The company has been active since 2009 and the Belgian State Gazette contains no insolvency or warning signals.
Signals
Three signals. The signal on the left, the evidence on the right.
○neutral
neutral · Latest accounts filed on time
The financial year that closed on 31-03-2025 was due by 31-10-2025 and was filed on 30-10-2025, 1 day ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
1 d early
2024
1 d early
2023
1 d early
2022
13 d early
2021
12 d early
2020
13 d late
2019
1 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-03-2026 and is due by 31-10-2026. Nothing is late today.
Companies Code · seven monthsPosition in the running window
31-03-2026 close13-09-2026 today31-10-2026 deadline
Financials · fiscal year 2025, abbreviated schema
Equity
€3.83M▲ 7.6%
2024 · €3.56M
2019: €2.18M
2020: €2.44M
2021: €3.23M
2022: €3.42M
2023: €3.55M
2024: €3.56M
2019 → 2025
Net result
€271k▲ 149%
2024 · €109k
2019: €103k
2020: €215k
2021: €760k
2022: €283k
2023: €235k
2024: €109k
2019 → 2025
Total assets
€10.88M▲ 23.7%
2024 · €8.79M
2019: €6.04M
2020: €6.22M
2021: €7.21M
2022: €7.66M
2023: €8.25M
2024: €8.79M
2019 → 2025
Solvency
35.2%▼ 5.3pp
2024 · 40.5%
2019: 36.1%
2020: 39.2%
2021: 44.8%
2022: 44.6%
2023: 43.0%
2024: 40.5%
2019 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€3.23M-€3.42M▲ 5.7%€3.55M▲ 3.9%€3.56M▲ 0.2%€3.83M▲ 7.6%
Operating result€1.04M-€450k▼ 56.8%€391k▼ 13.3%€230k▼ 41.0%€452k▲ 96.2%
Net result€760k-€283k▼ 62.7%€235k▼ 17.2%€109k▼ 53.6%€271k▲ 149%
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result recovers in 2025; 2025 is 96% above 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €10.88M
Fixed assets
€9.53M▲ 32.6%
Current assets
€1.35M▼ 15.9%
Equity and liabilities €10.88M
Equity
€3.83M▲ 7.6%
Provisions
€153k▼ 6.7%
Debt
€6.90M▲ 36.0%
The debt ratio rises from 57.6% to 63.4%: debt grows faster than equity.
Key figures and ratios
Solvency
35.2%▼
2024 · 40.5%
ROE
7.1%▲
2024 · 3.1%
ROA
2.5%▲
2024 · 1.2%
Debt
€6.90M▲
2024 · €5.07M
Debt ≤ 1 year
€4.27M▲
2024 · €3.48M
Debt > 1 year
€2.62M▲
2024 · €1.59M
Income taxes
€115k▲
2024 · €66k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€8.79M€10.88M▲
Fixed assets21/28€7.19M€9.53M▲
Intangible fixed assets21€1k€145▼
Tangible fixed assets22/27€3.43M€5.53M▲
Land and buildings22€2.56M€2.46M▼
Plant, machinery and equipment23€2k€1k▼
Furniture and vehicles24€42k€27k▼
Assets under construction and advance payments27€829k€3.04M▲
Financial fixed assets28€3.75M€4.00M▲
Current assets29/58€1.61M€1.35M▼
Amounts receivable after more than one year29€576k€592k▲
Other amounts receivable291€576k€592k▲
Amounts receivable within one year40/41€921k€694k▼
Trade receivables40€437k€509k▲
Other amounts receivable41€484k€185k▼
Current investments50/53€23k€23k=
Cash at bank and in hand54/58€70k€16k▼
Deferred charges and accrued income490/1€16k€26k▲
Equity and liabilities
Total equity and liabilities10/49€8.79M€10.88M▲
Equity10/15€3.56M€3.83M▲
Contributions10/11€19k€19k=
Reserves13€3.54M€3.81M▲
Tax-exempt reserves132€496k€463k▼
Distributable reserves133€3.05M€3.35M▲
Provisions and deferred taxes16€164k€153k▼
Deferred taxes168€164k€153k▼
Amounts payable17/49€5.07M€6.90M▲
Amounts payable after more than one year17€1.59M€2.62M▲
Financial debts170/4€1.59M€2.62M▲
Amounts payable within one year42/48€3.48M€4.27M▲
Current portion of amounts payable after more than one year42€574k€530k▼
Financial debts43€141k€230k▲
Credit institutions430/8€141k€230k▲
Trade debts44€198k€526k▲
Suppliers440/4€198k€526k▲
Taxes, remuneration and social security45€76k€88k▲
Taxes450/3€76k€88k▲
Other amounts payable47/48€2.49M€2.90M▲
Accrued charges and deferred income492/3€5k€6k▲
Income statement
Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€159k€154k▼
Other operating charges640/8€36k€30k▼
Gross operating margin9900€426k€636k▲
Operating profit (loss)9901€230k€452k▲
Financial income75/76B€26k€17k▼
Recurring financial income75€26k€17k▼
Financial charges65/66B€93k€94k▲
Recurring financial charges65€93k€94k▲
Profit (loss) for the period before taxes9903€164k€376k▲
Transfer from deferred taxes780€11k€11k=
Income taxes67/77€66k€115k▲
Profit (loss) for the period9904€109k€271k▲
Transfer from tax-exempt reserves789€33k€33k=
Profit (loss) for the period to be appropriated9905€142k€304k▲
Appropriation of the result
Profit (loss) to be appropriated9906€142k€304k▲
Transfer to equity691/2€42k€304k▲
To other reserves6921€42k€304k▲
Profit to be distributed694/7€100k-
Return on contributions (dividend)694€100k-
The notes to these accounts (20 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
17-08
State Gazette act
General meeting · Director reappointment
Director resignation
2025
30-10
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2024
30-10
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2023
30-10
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2022
18-10
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2021
19-10
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
31-03
Financial
Highest result since 2019net €760k ▲254%
Operating result €1.04M, net result €760k, both a record.
2020
13-11
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema · 13 days late
2019
30-10
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
2018
18-10
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2017
31-10
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
2016
27-10
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
6 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Oostende · 2 establishment units since 2009
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Gistelsesteenweg 188400 OostendeGround area
1.0 ha
Building footprint
2,958 m²
Volume, LiDAR
751 m³
2 parcels, Flanders · tallest building 11.7 m, ±3 floors. Linked by address, not a title deed.
2 establishment units
DECURA PHARMA
since 20092.180.322.745
Waalkens 11, 9030 Gent
since 20262.389.823.444
2 parcels
Flanders
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 44038A0046/00C002 | Flanders | 9,704 m² | 1 · 2,861 m² | - |
| 35383C0285/00X005 | Flanders | 425 m² | 1 · 97 m² | 11.7 m · 3 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Structure & network
Ownership & control
1 partyDECURA PHARMABE 0817.127.010
controls
Where this company holds controlthis company sits on their board1
1 location
Similar companies · same sector, comparable size
ROCAF
BE 0439.262.520
Antwerpen · Eq €3.83M
COMAVOR
BE 0463.701.372
Wuustwezel · Eq €3.83M
Houtvezelland Bioflam
BE 0445.601.964
Dessel · Eq €3.83M
BEAUTIFUL SOUTH
BE 0713.888.029
Meise · Eq €3.84M
DUMPRO INTERNATIONAL
BE 0894.892.207
Sint-Martens-Latem · Eq €3.84M
Of 24,640 companies in sector 64210 we hold annual accounts for 19,693. 8,934 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded15-07-2009
Fiscal year end31-03
Activities, NACEBEL
64200Holdings
64210Activities of holding companies
70100Activities of head offices
70200Business and other management consultancy
Sources
Crossroads Bank for EnterprisesNational Bank · 15 filingsAddress and cadastre registers
Data from official sources, last processed on 13-09-2026. Scores and ratios are computed by Checked and are not a credit decision.